ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease ...
Accurate measurement of HMGB-1, neopterin and sIL-2R supports reliable assessment of immune activation across clinical and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results